|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zeng H, Zheng R, Guo Y, Zhang S, Zou X,
Wang N, Zhang L, Tang J, Chen J, Wei K, et al: Cancer survival in
China, 2003–2005: A population-based study. Int J Cancer.
136:1921–1930. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhou C, Wu YL, Chen G, Feng J, Liu XQ,
Wang C, Zhang S, Wang J, Zhou S, Ren S, et al: Erlotinib versus
chemotherapy as first-line treatment for patients with advanced
EGFR mutation-positive non-small-cell lung cancer (OPTIMAL,
CTONG-0802): A multicentre, open-label, randomised, phase 3 study.
Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Maemondo M, Inoue A, Kobayashi K, Sugawara
S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I,
et al: Gefitinib or chemotherapy for non-small-cell lung cancer
with mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lynch TJ, Bell DW, Sordella R,
Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat
SM, Supko JG, Haluska FG, et al: Activating mutations in the
epidermal growth factor receptor underlying responsiveness of
non-small-cell lung cancer to gefitinib. N Engl J Med.
350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Han JY, Park K, Kim SW, Lee DH, Kim HY,
Kim HT, Ahn MJ, Yun T, Ahn JS, Suh C, et al: First-SIGNAL:
First-line single-agent iressa versus gemcitabine and cisplatin
trial in never-smokers with adenocarcinoma of the lung. J Clin
Oncol. 30:1122–1128. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Takezawa K, Pirazzoli V, Arcila ME, Nebhan
CA, Song X, de Stanchina E, Ohashi K, Janjigian YY, Spitzler PJ,
Melnick MA, et al: HER2 amplification: A potential mechanism of
acquired resistance to EGFR inhibition in EGFR-mutant lung cancers
that lack the second-site EGFRT790M mutation. Cancer Discov.
2:922–933. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pao W, Miller VA, Politi KA, Riely GJ,
Somwar R, Zakowski MF, Kris MG and Varmus H: Acquired resistance of
lung adenocarcinomas to gefitinib or erlotinib is associated with a
second mutation in the EGFR kinase domain. PLoS Med. 2:e732005.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Garofalo M, Romano G, Di Leva G, Nuovo G,
Jeon YJ, Ngankeu A, Sun J, Lovat F, Alder H, Condorelli G, et al:
EGFR and MET receptor tyrosine kinase-altered microRNA expression
induces tumorigenesis and gefitinib resistance in lung cancers. Nat
Med. 18:74–82. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gao Y, Fan X, Li W, Ping W, Deng Y and Fu
X: miR-138-5p reverses gefitinib resistance in non-small cell lung
cancer cells via negatively regulating G protein-coupled receptor
124. Biochem Biophys Res Commun. 446:179–186. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shi L, Wang Y, Lu Z, Zhang H, Zhuang N,
Wang B, Song Z, Chen G, Huang C, Xu D, et al: miR-127 promotes EMT
and stem-like traits in lung cancer through a feed-forward
regulatory loop. Oncogene. 36:1631–1643. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Horn L, Lovly CM and Johnson DH: Chapter
107: Neoplasms of the lung. Harrison's Principles of Internal
Medicine. Kasper DL, Hauser SL, Jameson JL, Fauci AS, Longo DL and
Loscalzo J: 19th. McGraw-Hill; New York, NY: 2015
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hua K, Yang W, Song H, Song J, Wei C, Li D
and Fang L: Up-regulation of miR-506 inhibits cell growth and
disrupt the cell cycle by targeting YAP in breast cancer cells. Int
J Clin Exp Med. 8:12018–12027. 2015.PubMed/NCBI
|
|
17
|
Wang Y, Cui M, Sun BD, Liu FB, Zhang XD
and Ye LH: MiR-506 suppresses proliferation of hepatoma cells
through targeting YAP mRNA 3′UTR. Acta Pharmacol Sin. 35:1207–1214.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Guo X, Xiao H, Guo S, Dong L and Chen J:
Identification of breast cancer mechanism based on weighted gene
coexpression network analysis. Cancer Gene Ther. 24:333–341. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li J, Wu H, Li W, Yin L, Guo S, Xu X,
Ouyang Y, Zhao Z, Liu S, Tian Y, et al: Downregulated miR-506
expression facilitates pancreatic cancer progression and
chemoresistance via SPHK1/Akt/NF-κB signaling. Oncogene.
35:5501–5514. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Krawczyk P, Powrozek T, Olesinski T,
Powrózek T, Olesiński T, Dmitruk A, Dziwota J, Kowalski D and
Milanowski J: Evaluation of miR-506 and miR-4316 expression in
early and non-invasive diagnosis of colorectal cancer. Int J
Colorectal Dis. 32:1057–1060. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yin M, Ren X, Zhang X, Luo Y, Wang G,
Huang K, Feng S, Bao X, Huang K, He X, et al: Selective killing of
lung cancer cells by miRNA-506 molecule through inhibiting NF-κB
p65 to evoke reactive oxygen species generation and p53 activation.
Oncogene. 34:691–703. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Guo S, Yang P, Jiang X, Li X, Wang Y,
Zhang X, Sun B, Zhang Y and Jia Y: Genetic and epigenetic silencing
of mircoRNA-506-3p enhances COTL1 oncogene expression to foster
non-small lung cancer progression. Oncotarget. 8:644–657.
2017.PubMed/NCBI
|
|
23
|
Yu HA, Arcila ME, Rekhtman N, Sima CS,
Zakowski MF, Pao W, Kris MG, Miller VA, Ladanyi M and Riely GJ:
Analysis of tumor specimens at the time of acquired resistance to
EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.
Clin Cancer Res. 19:2240–2247. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Engelman JA, Zejnullahu K, Mitsudomi T,
Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen
J, et al: MET amplification leads to gefitinib resistance in lung
cancer by activating ERBB3 signaling. Science. 316:1039–1043. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yano S, Yamada T, Takeuchi S, Tachibana K,
Minami Y, Yatabe Y, Mitsudomi T, Tanaka H, Kimura T, Kudoh S, et
al: Hepatocyte growth factor expression in EGFR mutant lung cancer
with intrinsic and acquired resistance to tyrosine kinase
inhibitors in a Japanese cohort. J Thorac Oncol. 6:2011–2017. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yu Q, Liu Y, Wen C, Zhao Y, Jin S, Hu Y,
Wang F, Chen L, Zhang B, Wang W, et al: MicroRNA-1 inhibits
tumorigenicity of esophageal squamous cell carcinoma and enhances
sensitivity to gefitinib. Oncol Lett. 15:963–971. 2018.PubMed/NCBI
|
|
27
|
Ping W, Gao Y, Fan X, Li W, Deng Y and Fu
X: MiR-181a contributes gefitinib resistance in non-small cell lung
cancer cells by targeting GAS7. Biochem Biophys Res Commun.
495:2482–2489. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhou H, Lin C, Zhang Y, Zhang X, Zhang C,
Zhang P, Xie X and Ren Z: miR-506 enhances the sensitivity of human
colorectal cancer cells to oxaliplatin by suppressing MDR1/P-gp
expression. Cell Prolif. 50:2017. View Article : Google Scholar :
|
|
29
|
Liu G, Xue F and Zhang W: miR-506: A
regulator of chemo-sensitivity through suppression of the
RAD51-homologous recombination axis. Chin J Cancer. 34:485–487.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pan D: The hippo signaling pathway in
development and cancer. Dev Cell. 19:491–505. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Harvey KF, Zhang X and Thomas DM: The
hippo pathway and human cancer. Nat Rev Cancer. 13:246–257. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yu S, Cai X, Wu C, Wu L, Wang Y, Liu Y, Yu
Z, Qin S, Ma F, Thiery JP and Chen L: Adhesion glycoprotein CD44
functions as an upstream regulator of a network connecting ERK, AKT
and Hippo-YAP pathways in cancer progression. Oncotarget.
6:2951–2965. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ghiso E, Migliore C, Ciciriello V, Morando
E, Petrelli A, Corso S, De Luca E, Gatti G, Volante M and Giordano
S: YAP-dependent AXL overexpression mediates resistance to EGFR
inhibitors in NSCLC. Neoplasia. 19:1012–1021. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
McGowan M, Kleinberg L, Halvorsen AR,
Helland Å and Brustugun OT: NSCLC depend upon YAP expression and
nuclear localization after acquiring resistance to EGFR inhibitors.
Genes Cancer. 8:497–504. 2017.PubMed/NCBI
|
|
35
|
Hua K, Yang W, Song H, Song J, Wei C, Li D
and Fang L: Up-regulation of miR-506 inhibits cell growth and
disrupt the cell cycle by targeting YAP in breast cancer cells. Int
J Clin Exp Med. 8:12018–12027. 2015.PubMed/NCBI
|
|
36
|
Wang Y, Cui M, Sun BD, Liu FB, Zhang XD
and Ye LH: MiR-506 suppresses proliferation of hepatoma cells
through targeting YAP mRNA 3′UTR. Acta Pharmacol Sin. 35:1207–1214.
2014. View Article : Google Scholar : PubMed/NCBI
|
